Health Care·Pharmaceuticals·$153.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.78 | N/A | -0.21% |
management commentary, guidance changes, and full analysis available with Pro.
| -0.21% |
Tone: Cautiously Optimistic
Overall, management acknowledged the competitive landscape while expressing confidence in their future product pipeline. They did not provide specific guidance for the upcoming quarters.
Management highlighted ongoing challenges in the market.
They emphasized a focus on innovation and pipeline development.
Pfizer's earnings report showed a slight miss on EPS, which contributed to a 0.79% decline in stock price. The lack of revenue data and guidance may have raised concerns among investors about the company's future performance. Management's cautious tone suggests they are aware of market challenges but remain focused on their product development efforts.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
WASTE CONNECTIONS IN
Oct 29, 2018